Method for the analysis of related substances in cyclosporine a preparation, and use thereof
View Patent ↗A method for analysis of related substances in a cyclosporine A preparation is provided. Chromatographic conditions for the method are as follows: a detection wavelength: 210 nm to 230 nm; a column temperature: 50° ° C. to 60° C.; a flow rate: 0.8 mL/min to 1.5 mL/min; a mobile phase A: acetonitrile (0.085% phosphoric acid); a mobile phase B: isopropanol (0.085% phosphoric acid); and a mobile phase C: water (0.1% phosphoric acid). The method of the present disclosure can well solve problems such as interference of adjuvants and poor separation of many related substances, and also provides an effective means for formulation of quality standards for related substances in such a preparation.
1 . A method for an analysis of related substances in a cyclosporine A preparation, wherein the method refers to high-performance liquid chromatography, and is conducted under the following conditions: a chromatographic column with octadecylsilane-bonded silica gel as a packing; and mobile phases comprising: a mobile phase A, a mobile phase B, and a mobile phase C, wherein the mobile phase A is a phosphoric acid-acetonitrile solution with a concentration of phosphoric acid being 0.05% to 0.1%; the mobile phase B is a phosphoric acid-isopropanol solution with a concentration of phosphoric acid being 0.05% to 0.1%; and the mobile phase C is a phosphoric acid aqueous solution with a concentration of phosphoric acid being 0.05% to 0.2%.
2 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein a detection wavelength for the high-performance liquid chromatography is 210 nm to 230 nm.
3 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein a column temperature for the high-performance liquid chromatography is 50° C. to 60° C.
4 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein a flow rate for the high-performance liquid chromatography is 0.8 mL/min to 1.5 mL/min.
5 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein the chromatographic column for the high-performance liquid chromatography is one or more of a Waters chromatographic column, an Agilent chromatographic column, a Thermo chromatographic column, a Phenomenex chromatographic column, a Shimatsu chromatographic column, or a YMC chromatographic column.
6 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein the high-performance liquid chromatography adopts a gradient elution as follows:
0 min to 20 min: the mobile phases comprise 50% of the mobile phase A and 50% of the mobile phase C, and a flow rate is 1.00 mL/min;
20 min to 100 min: the mobile phases comprise 35% of the mobile phase A, 20% of the mobile phase B, and 45% of the mobile phase C, and a flow rate is 1.50 mL/min; and
after 100 min: the mobile phases comprise 50% of the mobile phase A and 50% of the mobile phase C, and a flow rate is 1.00 mL/min.
7 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein the related substances comprise polyoxyethylene (35) castor oil.
8 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein the related substances comprise one or more of cyclosporine B, cyclosporine C, cyclosporine D, cyclosporine H, iso-cyclosporine A, and iso-cyclosporine H.
9 . The method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 , wherein the cyclosporine A preparation is a gel preparation.
10 . A method for preparing a cyclosporine A preparation with a pharmaceutically-acceptable purity, comprising using the method for the analysis of the related substances in the cyclosporine A preparation according to claim 1 .
11 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, a detection wavelength for the high-performance liquid chromatography is 210 nm to 230 nm.
12 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, a column temperature for the high-performance liquid chromatography is 50° ° C. to 60° C.
13 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, a flow rate for the high-performance liquid chromatography is 0.8 mL/min to 1.5 mL/min.
14 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, the chromatographic column for the high-performance liquid chromatography is one or more of a Waters chromatographic column, an Agilent chromatographic column, a Thermo chromatographic column, a Phenomenex chromatographic column, a Shimatsu chromatographic column, or a YMC chromatographic column.
15 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, the high-performance liquid chromatography adopts a gradient elution as follows:
0 min to 20 min: the mobile phases comprise 50% of the mobile phase A and 50% of the mobile phase C, and a flow rate is 1.00 mL/min;
20 min to 100 min: the mobile phases comprise 35% of the mobile phase A, 20% of the mobile phase B, and 45% of the mobile phase C, and a flow rate is 1.50 mL/min; and
after 100 min: the mobile phases comprise 50% of the mobile phase A and 50% of the mobile phase C, and a flow rate is 1.00 mL/min.
16 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, the related substances comprise polyoxyethylene (35) castor oil.
17 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, the related substances comprise one or more of cyclosporine B, cyclosporine C, cyclosporine D, cyclosporine H, iso-cyclosporine A, and iso-cyclosporine H.
18 . The method for preparing the cyclosporine A preparation with the pharmaceutically-acceptable purity according to claim 10 , wherein in the method for the analysis of the related substances in the cyclosporine A preparation, the cyclosporine A preparation is a gel preparation.